针对表皮生长因子受体的affibody衍生药物结合物是强大的和特定的细胞毒剂
Sara S Rinne1, Wen Yin2, Ruonan Li2
1Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.
ACS pharmacology & translational science
|November 20, 2025
概括
一种针对表皮生长因子受体 (EGFR) 的新型附体基药物结合体显示出强大的抗癌活性. 这种新的治疗候选药物表明,它有望克服EGFR驱动癌症的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 过度活跃的表皮生长因子受体 (EGFR) 信号驱动各种癌症.
- 目前针对EGFR的治疗方法 (单克隆抗体,激酶抑制剂) 面临耐药性.
- 对抗EGFR驱动的癌症需要新的治疗策略.
研究的目的:
- 开发和表征一种新的EGFR向药物合物类.
- 在临床前模型中评估基于亲体的药物合物 (Z_EGFR-ABD-mcDM1) 的疗效.
主要方法:
- 设计了一种附属体分子 (Z_EGFR),与蛋白结合域 (ABD) 融合,并与细胞毒药物DM1.1结合.
- 对复合EGFR和EGFR表达细胞的评估结合亲缘关系.
- 在体外对A431细胞的细胞毒性确定.
- 在A431异种移植模型中评估了体内疗效.
主要成果:
- 这种Z_EGFR-ABD-mcDM1结合体表现出强烈的结合EGFR.
- 在杀死EGFR表达A431细胞 (IC50=3.4nM) 中表现出高强度.
- 在EGFR表达异种移植中体内显示中度瘤吸收.
结论:
- Z_EGFR-ABD-mcDM1是一种强效和特定的EGFR向药物候选药物.
- 这种新型结合物对治疗EGFR驱动的癌症具有前途.
- 这种新的治疗方式需要进一步发展.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K


